Pfizer decided to think bigger and to in-license SSGJ-707 from 3SBio. The deal allows increased ... much lower financial risks than an outright acquisition of a company like Summit.

Recently, BioNTech SE announced an $800 million acquisition of Biotheus ... subject to customary regulatory approvals and 3SBio shareholder consent. Upon completion, Pfizer will also make a $100 ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

The acquisition of SSGJ-707 coincides with Pfizer and Summit collaborating on ... stated that no changes are expected when asked how the 3SBio deal would impact its partnership with Summit.

Here's a recap of the week’s most important stories.

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

The acquisition will add Vigil’s investigational ... Pfizer’s New Deal for PD-1/VEGF inhibitor With China’s 3SBio Pfizer announced an exclusive deal to acquire global (ex-China) rights ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...